Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data

Biological disease-modifying antirheumatic drugs (bDMARDs) monotherapy may enhance adherence and decrease adverse events compared to combination therapy with conventional synthetic DMARDs (csDMARDs); however, persistence with bDMARD monotherapy has not been extensively studied. We explore persistenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappas, Dimitrios A., Litman, Heather J., Lesperance, Tamara, Kricorian, Greg, Karis, Elaine, Rebello, Sabrina, Hua, Winnie, Accortt, Neil A., Stryker, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Observational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835165/
https://www.ncbi.nlm.nih.gov/pubmed/32876744
http://dx.doi.org/10.1007/s00296-020-04667-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835165/
https://www.ncbi.nlm.nih.gov/pubmed/32876744
http://dx.doi.org/10.1007/s00296-020-04667-5

Ejemplares similares